Research on chemotherapy-induced nausea: Back to the past for an unmet need?

Journal of Clinical Oncology

Volumn 31, Issue 10, 2013, Pages 1376-1377

  Celio, Luigi ^a   Aapro, Matti ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; PALONOSETRON; PROCHLORPERAZINE;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DELAYED NAUSEA; DRUG EFFICACY; HUMAN; LETTER; NAUSEA; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NAUSEA;

EID: 84876089397     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.2209     Document Type: Letter

References (10)

1. Olver I, Molassiotis A, Aapro M, et al: Antiemetic research: Future directions. Support Care Cancer 19:S49-S55, 2011 (suppl 1)
2. Roscoe JA, Heckler CE, Morrow GR, et al: Prevention of delayed nausea: A University of Rochester Cancer Center Community Oncology Program study of patients receiving chemotherapy. J Clin Oncol 30:3389-3395, 2012
3. Celio L, Frustaci S, Denaro A, et al: Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: A randomized, multi center, phase III trial. Support Care Cancer 19:1217-1225, 2011
4. Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
5. The Italian Group for Antemetic Research: Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients? The Italian Group for Antemetic Research. Ann Oncol 8:561-567, 1997
6. The Italian Group for Antemetic Research: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy: The Italian Group for Antemetic Research. N Engl J Med 342:1554-1559, 2000
7. Hickok JT, Roscoe JA, Morrow GR, et al: 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: A URCC CCOP randomised controlled trial. Lancet Oncol 6:765-772, 2005 (Pubitemid 41430717)
8. Celio L, Bonizzoni E, Bajetta E, et al: Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 21:565-573, 2013
9. Roila F, Herrstedt J, Aapro M, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 21:v232-v243, 2010 (suppl 5)
10. Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189-4198, 2011